On April 7, 2026, a Louisiana federal court paused a lawsuit challenging FDA’s 2023 mifepristone REMS, allowing telehealth prescribing, pharmacy dispensing, and mail distribution to remain while the agency conducts a safety review.
Written By: Samiksha Jadhav, BPharm
Reviewed By: Pharmacally Editorial Team
On April 7, 2026, a U.S. federal court in Louisiana paused litigation challenging the U.S. Food and Drug Administration’s (FDA) 2023 safety framework for mifepristone, allowing the agency to complete an ongoing review of the drug’s Risk Evaluation and Mitigation Strategy (REMS). The decision keeps current telehealth prescribing, pharmacy dispensing, and mail distribution rules in place while the regulator reassesses whether modifications are necessary.
Court stays case instead of granting emergency relief
The lawsuit was filed on October 6, 2025, by the State of Louisiana and a private plaintiff against the FDA and federal health officials, challenging the removal of in-person dispensing requirements and the allowance of telehealth prescribing, pharmacy dispensing, and mail distribution of mifepristone. The plaintiffs sought preliminary relief to reinstate stricter controls.
In its April 7, 2026 memorandum ruling, the court denied that request and instead granted the government’s motion to stay the case. The ruling pauses further litigation until the FDA completes its safety review, with motions from both plaintiffs and drug manufacturers denied without prejudice.
FDA safety reassessment central to the ruling
The court emphasized that the FDA is already conducting a comprehensive evaluation of mifepristone safety and the current REMS. In a September 19, 2025 communication, federal health leadership stated the review would analyze reported adverse events and assess whether existing safeguards adequately protect patients. The agency indicated that the reassessment would be grounded in evidence-based analysis.
The court concluded that allowing the FDA to complete this review, rather than issuing immediate judicial intervention, better serves the public interest and respects the agency’s scientific role.
Manufacturers intervene to defend current framework
On February 24, 2026, the court granted motions by mifepristone manufacturers Danco Laboratories and GenBioPro to intervene in the case and file motions to dismiss. In the April 7, 2026 ruling, the court denied those motions without prejudice, noting they may be renewed after the FDA completes its review and the stay is lifted.
Court finds standing but favors regulatory review
In the April 7, 2026 decision, the court determined Louisiana had standing based on alleged sovereign and financial harms linked to the 2023 REMS. However, it concluded that the appropriate course is to allow the FDA to complete its promised review, particularly given the agency’s authority to evaluate drug safety and modify REMS requirements if needed.
Reference
Memorandum Ruling – Louisiana v. FDA (Apr 7, 2026) available at https://litigationtracker.law.georgetown.edu/wp-content/uploads/2025/10/Louisiana_2026.04.07_OPINION.pdf
Questions and Answers on Mifepristone for Medical Termination of Pregnancy Through Ten Weeks Gestation, 08 April 2026, https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/questions-and-answers-mifepristone-medical-termination-pregnancy-through-ten-weeks-gestation
About the Writer
Samiksha Vikram Jadhav is a B.Pharm graduate with a strong academic foundation in pharmaceutical sciences, pharmacology, and drug development. She has a keen interest in healthcare advancements, clinical research, medical writing, and emerging therapies. Her work focuses on presenting developments in the pharmaceutical and healthcare sectors through clear and accurate scientific communication.
